Indivior Share Discussion Threads

[ljhrunner12] 22/6/2018 17:38

That's actually a recent reduction in reported short positions on 20th June, which more than offset the last reported increase back at the start of March.

[steeplejack] 22/6/2018 10:10

Short positions building recently Companies » INDIVIOR PLC Disclosed positions in INDIVIOR PLC (INDV)Notice: We no longer track disclosures after they drop below 0.5%. It is possible that the manager still holds a short position even if we are showing it as zero.Fund % short change Date changedPartner Fund Management, L.P. 0.92% 0.0% 15 Jun 2018Point72 Asset Management, L.P. 0.69% -0.21% 20 Jun 2018Wellington Management Company, LLP 0.84% 0.13% 1 Mar 2018Total 2.45%

[steeplejack] 18/6/2018 10:14

Post the Dr Reddy news,Jeffries reiterates buy with a 630p price target on June 15th.


Moodys hangs over the stock like the sword of Damoclese

[sarkasm] 18/6/2018 09:33

U.K. pharmaceutical company Indivior PLC (INDV.LN) said Monday that it has been successful in blocking--for the time being--the launch of a generic alternative to its Suboxone opioid disorder medication through the courts.

It said that the U.S. district court of New Jersey had granted it a restraining order compelling rival drugmaker Dr. Reddy's to temporarily cease activities related to the development and marketing of the product.

The order will stay until a hearing can take place on a preliminary injunction motion filed by Indivior. The company said it seeks to extend the ban on a launch of a generic Suboxone alternative.



Write to Carlo Martuscelli at [e-mail]



(END) Dow Jones Newswires

June 18, 2018 02:50 ET (06:50 GMT)

[sarkasm] 18/6/2018 08:51

Oliver Haill
WebFG News
18 Jun, 2018 08:36
Indivior hails court order blocking Dr Reddy's suboxone launch
indivior, invidior, suboxone
Indivior
374.20
08:33:37 18/06/18
3.80%
13.70
FTSE 250
20,963.75
08:33:47 18/06/18
-0.20%
-41.77
FTSE 350
4,257.08
08:33:47 18/06/18
-0.11%
-4.86
FTSE All-Share
4,205.68
08:33:47 18/06/18
-0.10%
-4.26

Indivior has won a temporary restraining order by a US court compelling rival drugmaker Dr Reddy's Labs to immediately stop any launch activities related to its generic version of Suboxone Film.

The US District Court for the District of New Jersey's restraining order will remain in place at least until a hearing on the preliminary injunction motion that Indivior filed on Friday when Dr Reddy’s won approval from the US drug regulator to produce a generic version of the sublingual film, which is used as a treatment for opioid addiction.

Dr Reddy's announced the approval from US Food & Drug Administration and said it would launch the buprenorphine and naloxone film.

This statement to launch was despite Indivior having recently filed litigation against Dr Reddy's and others related to the '305 patent.

On Monday, Indivior said it aimed to use the district court hearing, for which a preliminary injunction motion has been scheduled for 28 June, to seek to stop Dr Reddy's from launching its generic film pending the outcome of that litigation.

Chief executive Shaun Thaxter said: "We are pleased that the court has granted our request for a temporary restraining order. This order will stop Dr Reddy's launch activities before the court has had a chance to rule on the preliminary injunction motion. We will continue to pursue all legal avenues against Dr Reddy's to protect our Suboxone Film patent estate."

[dealy] 16/6/2018 14:08

makes sense Kazoom

[kazoom] 16/6/2018 12:58

I am new to Indivior so apologies if this doesn't make sense - please feel free to correct me ;-)

When I read "So Dr Reddy is really interested in testing punitive damages! I do wonder."

I wonder if Dr Reddy are actually engaged in some Trump style bargaining.

I note here (14-may) that INDV settled with PAR phara and that Par get the ability to sell the generic from Jan 2023

Maybe Reddy are angling for a similar settlement?

Also if Par don't have the rights until 2023 - why would we expect the courts to grant a later comer like Reddy earlier access to the market?

On that basis (and of course it could be nonsense) it seems to be that the outcome is likely to be much better than Friday's share price movement would suggest.

Any thoughts?

[steeplejack] 16/6/2018 08:39

https://uk.investing.com/news/stock-market-news/indivior-shares-dive-after-dr-reddys-gets-fda-approval-for-generic-1215680

[dealy] 16/6/2018 07:44

Well they have secured a temporary restraining order so hopefully big bounce on Monday

[steeplejack] 15/6/2018 22:52

Thanks for your comment Greg.Always appreciated.They'll be burning the midnight oil in the Standard Life HQ off Charlotte Square tonight!The company's response is solid enough and the market's response today frenetic.When we have days like this,I understand why the number of listed companies on the LSE has halved in the last 20 years.Whether the reaction be justifiable or not,the feral reaction of the market on the day (with all the implicit implications for the company)must be the biggest advert for a firm to go private imaginable.

[gregmorg] 15/6/2018 17:48

So Dr Reddy is really interested in testing punitive damages! I do wonder. The emphasis has to be on building up the more lucrative sublocade even faster whilst protecting as much of the film market share. Taking the longer term view and doing nothing- as always!.Also interesting announcement from Standard Life. Am overseas currently but from what I could see it bought quite a slug and had no notifiable interest previously. Someone else sold the stake of course.

[steeplejack] 15/6/2018 17:05

4 sept 2017?The shares are even now a good 30% higher than when you wrote that post.I think when Trump shows concern about opioid addiction,all will be done to get generic medication at a reasonable price to those who need it.Just how quickly Dr Reddy get their "at risk" product to the market remains to be seen.We all knew this was coming,it was a question of when.The good news is that there's a new injectable on the block .To be honest,I'm not sure whether I should be panicking or not.

[buywell3] 15/6/2018 16:37

buywell3 - 04 Sep 2017 - 07:47:52 - 304 of 394 RB. de-merger - INDV
There will be other legal actions coming to courts in the USA soon

The RISK here is that that Indivior could lose the next one

What would be the market reaction then ?

What is the date for the next court case ?


''In September, 35 U.S. states and the District of Columbia filed a lawsuit against Indivior alleging that it tried to keep generic versions of a drug off the market.

The lawsuit by the states alleged that Indivior took steps to get patients to switch to the oral strip version of Suboxone.''






Investing is about weighing up risks

Buying this stock today IMO is a punt
dyor

[steeplejack] 15/6/2018 11:19

Hargreaves and others are reasonably sanguine on this news and past price behaviour suggests that you'll be rewarded if you buy the falls.I'm surprised that they managed to get the stock down to 370 but the shares have been strong of late,recently topping 5 quid which prompted UBS to turn to a neutral stance.Understandable concerns over Suboxone generics have long haunted the shares but the future is all about Sublocade approved in the USA last November.Generics might ultimately track down Suboxone film but during the chase Sublocade should be up and running.

[jonmy7] 15/6/2018 10:40

I saw this as a buying opportunity as, with my very limited experience, the company looks strong to me. Brought at 391, it's since dropped further but I'm holding as I expect it to rise over the next 10 days.

[steeplejack] 15/6/2018 08:40

As Sharecast comment,this is not unexpected news but the stock has been strong of late and this is an opportunity to knock the froth of the top.As ever,on these occasions,I usually take the opportunity to trade a few alongside a core holding.

[meijiman] 15/6/2018 08:36

Thanks for that Typo. Not sure if this is a buying opportunity or the the shares may drift down further.

[steeplejack] 15/6/2018 08:36

(Sharecast News) - Indivior's main revenue-generating product, Suboxone film, came under pressure overnight as rival Dr Reddy's Labs won regulatory approval to its generic version of the sublingual film.Dr Reddy's announced the approval from US Food & Drug Administration and said is launching buprenorphine and naloxone film to treat adults with opioid addiction.Suboxone had US sales of roughly $1.86bn for the most recent twelve months ending in April, according to IMS Health.The news, which saw Indivior's shares slide more than 15% lower 420p on Friday morning, was not unexpected as recent correspondence from the FDA for Dr Reddy's in the previous quarter, which suggested an approval was imminent.Analysts at RBC Capital Markets said that if Dr Reddy's was to launch 'at risk', that is before both a ruling on the current appeals process and a ruling on the three additional Orange Book listed patents, "then this would be a negative for Indivior and our current forecast assumptions".Indivior has reacted to losing a recent court case by suing companies who are developing generic versions of its opioid addiction treatment .In April, Slough-based Indivior filed patent lawsuits against generic drugmakers including Dr Reddy's for infringing a new US patent relating to their respective proposed generic versions of its Suboxone film.Indivior's lawsuits allege that the generic companies infringe the patent and comes on the back of other patent infringement litigation over its earlier issued patents covering Suboxone with the same companies.But not long after, the company reached a settlement to resolve patent litigation against Par Pharmaceutical, allowing Par to begin selling a generic version of Suboxone film from 1 January 2023.

[typo56] 15/6/2018 08:33

Dr Reddy's gets USFDA nod to launch generic Suboxone

[nateroyd] 15/6/2018 08:12

What's happening

[gregmorg] 05/6/2018 09:20

Interesting milestone this morning but will it hold over the £5 level. No news, that I can see.Later in the day Jeffries healthcare conference . 8.30 NY time so maybe something to do with that.